1788-08-5

Usage

Uses

Used in Pharmaceutical Research:
4-Ethynylbenzenesulfonamide is utilized as a building block for the development of new pharmaceutical compounds due to its unique chemical structure and potential medicinal properties.
Used in Organic Synthesis:
As a versatile chemical, 4-Ethynylbenzenesulfonamide is employed as a reagent in various chemical reactions, contributing to the synthesis of a wide range of organic compounds.
Used in Anti-Cancer Research:
4-Ethynylbenzenesulfonamide is studied for its potential as an anti-cancer agent, with research focusing on its ability to target and inhibit the growth of cancer cells.
Used in Anti-Inflammatory Applications:
4-Ethynylbenzenesulfonamide is also explored for its anti-inflammatory effects, which could be beneficial in the treatment of various inflammatory conditions.
Used as a Precursor in Synthesis:
4-Ethynylbenzenesulfonamide serves as a precursor for the synthesis of other organic compounds, highlighting its importance in the field of chemistry.

InChI:InChI=1/C8H7NO2S/c1-2-7-3-5-8(6-4-7)12(9,10)11/h1,3-6H,(H2,9,10,11)

Upstream product

• 701-34-8 4-bromo-benzenesulfonic acid amide 
• 1066-54-2 trimethylsilylacetylene 
• 1056474-58-8 (Z)-4-(2-bromovinyl)benzenesulfonamide 
• 138-36-3 p-bromobenzene sulfonic acid 
• 98-58-8 4-bromobenzenesulfonyl chloride 
• 775331-26-5 4-((trimethylsilyl)ethynyl)benzenesulfonamide 

Downstream Products

• 1017276-57-1 4-[4-(aminosulfonyl)phenyl]-1-(2',3',4'-tri-O-acetyl-β-D-glucuronic acid methyl ester)-1H-1,2,3-triazole 
• 1017276-60-6 4-[4-(aminosulfonyl)phenyl]-1-(2',3',4'-tri-O-acetyl-α-D-arabinopyranosyl)-1H-1,2,3-triazole 
• 1017276-59-3 4-[4-(aminosulfonyl)phenyl]-1-(2',3',4',6'-tetra-O-acetyl-α-D-mannopyranosyl)-1H-1,2,3-triazole 
• 1017276-56-0 4-[4-(aminosulfonyl)phenyl]-1-(2'-acetamido-2'-deoxy-3',4',6'-tri-O-acetyl-β-D-glucopyranosyl)-1H-1,2,3-triazole 
• 1017276-55-9 4-[4-(aminosulfonyl)phenyl]-1-(hepta-O-acetyl-β-D-maltopyranosyl)-1H-1,2,3-triazole 
• 1017276-52-6 4-[4-(aminosulfonyl)phenyl]-1-(2',3',4',6'-tetra-O-acetyl-β-D-glucopyranosyl)-1H-1,2,3-triazole 
• 1017276-54-8 4-[4-(aminosulfonyl)phenyl]-1-(2',3',4',6'-tetra-O-acetyl-β-D-galactopyranosyl)-1H-1,2,3-triazole 
• 1063716-25-5 1,4-di-(4-aminosulfonylbenzene)-1H-1,2,3-triazole 
• 1017276-62-8 4-[4-(aminosulfonyl)phenyl]-1-(β-D-galactopyranosyl)-1H-1,2,3-triazole 
• 1017276-61-7 4-[4-(aminosulfonyl)phenyl]-1-(β-D-glucopyranosyl)-1H-1,2,3-triazole 

Relevant academic research and scientific papers

INSULIN CONJUGATES

The present invention relates to a conjugate comprising a sulfonamide of formula (I) and an active pharmaceutical ingredient such as an insulin analog comprising at least one mutation relative to the parent insulin, wherein the insulin analog comprises a mutation at position B16 which is substituted with a hydrophobic amino acid and/or a mutation at position B25 which is substituted with a hydrophobic amino acid. The present invention further relates to a sulfonamide of formula (A). Moreover, the present invention relates to an insulin analog comprising at least one mutation relative to the parent insulin.

NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS

The invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.

Novel valdecoxib derivatives by ruthenium?II)-promoted 1, 3-dipolar cycloaddition of nitrile oxides with alkynes - Synthesis and COX-2 inhibition activity

Novel valdecoxib-based cyclooxygenase-2 inhibitors were synthesized in one step via 1, 3-dipolar cycloaddition of nitrile oxides with a series of eleven aryl alkynes, six of them described for the first time. Application of Ru?II)-catalysis leads preferab

NOVEL CONDENSED PYRAZOLE DERIVATIVE AND MEDICAL USES THEREOF

PROBLEM TO BE SOLVED: To provide a preventive or therapeutic agent for mood disorder, anxiety disorder, schizophrenia, dementia, drug dependence or the like related to subtypes of metabolism type glutamate receptor (mGlu) 2 and 3. SOLUTION: There are prov

RAFAMYCIN ANALOGS AND METHODS FOR MAKING SAME

A semi-synthetic rapamycin analog with a triazole moiety or a pharmaceutically acceptable salt or prodrug thereof, is a broad-spectrum cytostatic agent and a mTOR inhibitor, and is useful in the treatment of various cancers, or tumors in organs such as kidney, liver, breast, head and neck, lung, prostate, and restenosis in coronary arteries, peripheral arteries, and arteries in the brain, immune and autoimmune diseases. Also disclosed are fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosois, post-transplant tissue rejection, and immune and autoimmune disease in a mammal. One particular preferred application of such triazole-moiety containing rapamycin analog is in treating renal carcinoma, lung cancer, colon cancer, and breast cancers wherein potency of the drug, its half-life, tissue distribution properties, and its pharmacokinetic properties including bioavailability through oral and intravenous routes are essential to the clinical outcomes.

RAFAMYCIN ANALOGS AND METHODS FOR MAKING SAME

A semi-synthetic rapamycin analog with a triazole moiety or a pharmaceutically acceptable salt or prodrug thereof, is a broad-spectrum cytostatic agent and a m TOR inhibitor, and is useful in the treatment of various cancers, or tumors in organs such as kidney, liver, breast, head and neck, lung, prostate, and restenosis in coronary arteries, peripheral arteries, and arteries in the brain, immune and autoimmune diseases. Also disclosed are fungal growth-, restenosis-, post- transplant tissue rejection- and immune- and autoimmune disease- inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosois, post-transplant tissue rejection, and immune and autoimmune disease in a mammal. One particular preferred application of such triazole-moiety containing rapamycin analog is in treating renal carcinoma, lung cancer, colon cancer, and breast cancers wherein potency of the drug, its half-life, tissue distribution properties, and its pharmacokinetic properties including bioavailability through oral and intravenous routes are essential to the clinical outcomes.

ETHINYL-PYRAZOLE DERIVATIVE

Provided is a novel compound represented by formula [I] or a pharmaceutically acceptable salt thereof having antagonistic activity against group II metabolism-type glutamic acid (m-Glu) receptors. The compound or pharmaceutically acceptable salt thereof i

Efficient one-pot synthesis of 4-Ethynylbenzenesulfonamides

One-pot simultaneous debrominative decarboxylation and sulfamation of anti-2,3-dibromo-3-(4-chlorosulfonylphenyl)propanoic acid in DMF (for alkylamines) or DMF-pyridine (1/1, for arylamines) using a diverse range of alkyl and aryl amines under microwave i

Synthesis and cyclooxygenase inhibitory activities of linear 1-(methanesulfonylphenyl or benzenesulfonamido)-2-(pyridyl)acetylene regioisomers

A group of 1-(aminosulfonylphenyl and methylsulfonylphenyl)-2-(pyridyl)acetylene regioisomers were designed such that a COX-2 SO2NH2 pharmacophore was located at the para-position of the phenyl ring, or a SO2Me pharmacopho

Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides

A library of glycoconjugate benzene sulfonamides have been synthesized and investigated for their ability to inhibit the enzymatic activity of physiologically relevant human carbonic anhydrase (hCA) isozymes: hCA I, II, and tumor-associated IX. Our synthetic strategy directly links the known CA pharmacophore (ArSO2NH2) to a sugar tail moiety through a rigid 1,2,3-triazole linker unit using the Cu(I)-catalyzed 1,3-dipolar cycloaddition reaction or click chemistry . Many of the glycoconjugates were potent CA inhibitors and exhibited some isozyme selectivity. In particular, the methyl-D-glucuronate triazoles 6 and 14 were potent inhibitors of hCA IX (KiS 9.9 and 8.4 nM, respectively) with selectivity also favoring this isozyme. Other exceptional compounds included the deprotected β-D-ribofuranosyl triazole 15 and α-D-mannosyl triazole 17, which were potent and selective hCA II inhibitors (Ki 7.5 nM and Ki 2.3 nM, respectively). Collectively, the results confirm that modification of ring size, stereochemical configuration, and chain length in the sugar tail moiety of glycoconjugate CA inhibitors permits tunable potency and selectivity that may constitute an important avenue for the future development of efficacious and selective CA-based therapeutics.